HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates
Tóm tắt
HCV/HIV coinfection in people who inject drugs is a public health issue, which presents a variety of challenges to healthcare providers. The determinants of HCV/HIV coinfection in this population are nonetheless not well known. The aim of the present study is to identify the factors associated with HCV/HIV coinfection in people who inject drugs and enter drug-related treatment. Linked serological and behavioral data were collected from people who entered 38 opioid substitution treatment clinics in central and southern Greece between January and December 2013. Three mutually exclusive groups were defined based on the presence of HCV and HIV antibodies. Group 1 clients had neither infection, Group 2 had HCV but not HIV, and Group 3 had HCV/HIV coinfection. Multinomial logistic regression analyses identified differences between groups according to socio-demographic, drug use and higher-risk behavioral characteristics. Our study population consisted of 580 people who injected drugs in the past 12 months (79.8 % males, with median age 36 years).79.4 % were HCV and 15.7 % HIV infected. Of those with complete serological data in both HCV and HIV indicators, 20.4 % were uninfected, 64.0 % HCV monoinfected, and 14.9 % HCV/HIV coinfected. HCV infection with or without HIV coinfection was positively associated with living alone or with a spouse/partner without children, prior incarceration, drug injecting histories of ≥10 years, and syringe sharing in the past 12 months, and negatively associated with never having previously been tested for HCV. HCV/HIV coinfection, but not HCV infection alone, was positively associated with residence in urban areas (relative risk ratio [RRR] = 4.8, 95 % confidence interval [CI]: 1.7–13.7, p = 0.004) and averaging >3 injections a day in the past 30 days (RRR = 4.5, 95 % CI: 1.6–12.8, p = 0.005), and negatively associated with using a condom in the last sexual intercourse. People who inject drugs and live in urban areas and inject frequently have higher risk of coinfection. Findings highlight the need for scaling-up needle and syringe programs in inner city areas and promoting access of this population to screening and treatment, especially in prisons. The protective role of living with parents and children could inform the implementation of indicated interventions.
Tài liệu tham khảo
Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352–8.
Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS. 2005;19 Suppl 3:S199–207.
Strader DB. Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. Clin Infect Dis. 2005;41 Suppl 1:S7–13.
Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect. 2013;FirstView:1–17.
Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, Montaner JS, Schechter MT. The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr. 2004;36(2):743–9.
Rhodes T, Platt L, Judd A, Mikhailova LA, Sarang A, Wallis N, Alpatova T, Hickman M, Parry JV. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. Int J STD AIDS. 2005;16(11):749–54.
Vickerman P, Martin NK, Roy A, Beattie T, Group EC, Des Jarlais D, Strathdee S, Wiessing L, Hickman M. Is the HCV–HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend. 2013;132(1):172–81.
Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 Suppl):S6–9.
Lumbreras B, Jarrin I, del Amo J, Perez-Hoyos S, Muga R. Garcia-de la Hera M, Ferreros I, Sanvisens A, Hurtado I, Hernandez-Aguado I: Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS. 2006;20(1):111–6.
Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr. 2008;47(2):221–5.
Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. Int J Drug Policy. 2015;26(10):911–21.
Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34(6):1193–9.
Monto A, Currie S, Wright TL. Liver disease in injection drug users with hepatitis C, with and without HIV coinfection. J Addict Dis. 2008;27(2):49–59.
Sanvisens A, Fuster D, Serra I, Tor J, Tural C, Rey-Joly C, Muga R. Estimated liver fibrosis and its impact on all-cause mortality of HCV-monoinfected and HCV/HIV-coinfected drug users. Curr HIV Res. 2011;9(4):256–62.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.
Taylor LE, Swan T, Matthews GV. Management of Hepatitis C Virus/HIV Coinfection Among People Who Use Drugs in the Era of Direct-Acting Antiviral–Based Therapy. Clin Infect Dis. 2013;57 suppl 2:S118–24.
Khalsa JH, Kresina T, Sherman K, Vocci F. Medical management of HIV-hepatitis C virus coinfection in injection drug users. Clin Infect Dis. 2005;41 Suppl 1:S1–6.
Kresina TF, Bruce RD, Cargill VA, Cheever LW. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV. Clin Infect Dis. 2005;41 Suppl 1:S83–8.
McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis. 2005;41 Suppl 1:S89–95.
Baum MK, Jayaweera DT, Duan R, Sales S, Lai S, Rafie C, Regev A, Page JB, Berkman R, Campa A. Quality of life, symptomatology and healthcare utilization in HIV/HCV co-infected drug users in Miami. J Addict Dis. 2008;27(2):37–48.
Scheft H, Fontenette DC. Psychiatric barriers to readiness for treatment for hepatitis C Virus (HCV) infection among injection drug users: clinical experience of an addiction psychiatrist in the HIV-HCV coinfection clinic of a public health hospital. Clin Infect Dis. 2005;40 Suppl 5:S292–6.
Graham CS, Wells A, Edwards EM, Herren T, Tumilty S, Stuver SO, Samet JH, Nunes D, Horsburgh Jr CR, Koziel MJ. Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection. J Infect Dis. 2007;195(6):847–56.
Cescon A, Chan K, Raboud JM, Burchell AN, Forrest JI, Klein MB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, et al. Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history. AIDS. 2014;28(1):121–7.
Mehta SH, Thomas DL, Sulkowski MS, Safaein M, Vlahov D, Strathdee SA. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS. 2005;19 Suppl 3:S179–89.
Rey D, Carrieri MP, Spire B, Loubiere S, Dellamonica P, Gallais H, Cassuto GP, Gastaut JA, Obadia Y. Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment. J Urban Health. 2004;81(1):48–57.
Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Strathdee SA. 12 myths about HIV/AIDS and people who use drugs. Lancet. 2010;376(9737):208–11.
Graham CS. Hepatitis C and HIV Co-infection: Closing the Gaps. JAMA. 2015;313(12):1217–8.
Akselrod H, Grau LE, Barbour R, Heimer R. Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population. Am J Public Health. 2014;104(9):1713–21.
Fisher DG, Reynolds GL, Jaffe A, Perez MJ. Hepatitis and human immunodeficiency virus co-infection among injection drug users in Los Angeles County. California J Addict Dis. 2006;25(2):25–32.
Garten RJ, Zhang J, Lai S, Liu W, Chen J, Yu XF. Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis. 2005;41 Suppl 1:S18–24.
Del Fava E, Kasim A, Usman M, Shkedy Z, Hens N, Aerts M, Bollaerts K, Scalia Tomba G, Vickerman P, Sutton AJ. Joint modeling of HCV and HIV infections among injecting drug users in italy using repeated cross-sectional prevalence data. Stat Commun Infect Dis. 2011. http://dx.doi.org/10.2202/1948-4690.1009.
Solomon SS, Srikrishnan AK, Mehta SH, Vasudevan CK, Murugavel KG, Thamburaj E, Anand S, Kumar MS, Latkin C, Solomon S, et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr. 2008;49(3):327–32.
Marmor M, Des Jarlais DC, Cohen H, Friedman SR, Beatrice ST, Dubin N, el-Sadr W, Mildvan D, Yancovitz S, Mathur U, et al. Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS. 1987;1(1):39–44.
Mathei C, Shkedy Z, Denis B, Kabali C, Aerts M, Molenberghs G, Van Damme P, Buntinx F. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. J Viral Hepat. 2006;13(8):560–70.
Zocratto KB, Caiaffa WT, Proietti FA, Carneiro-Proietti AB, Mingoti SA, Ribeiro GJ. HCV and HIV infection and co-infection: injecting drug use and sexual behavior, AjUDE-Brasil I Project. Cad Saude Publica. 2006;22(4):839–48.
Dumchev KV, Soldyshev R, Qian HZ, Zezyulin OO, Chandler SD, Slobodyanyuk P, Moroz L, Schumacher JE. HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional survey. Harm Reduct J. 2009;6:23.
Bollepalli S, Mathieson K, Jasiurkowski B, Hillier A, Post J, Bhanu S, Martin D, Van Thiel DH, Nadir A. A comparison of risk factors for HCV-mono-infection, HIV-mono-infection, and HCV/HIV-co-infection in a community setting. Dig Dis Sci. 2008;53(2):517–21.
Bollepalli S, Mathieson K, Bay C, Hillier A, Post J, Van Thiel DH, Nadir A. Prevalence of risk factors for hepatitis C virus in HIV-infected and HIV/hepatitis C virus-coinfected patients. Sex Transm Dis. 2007;34(6):367–70.
Hosseini M, SeyedAlinaghi S, Kheirandish P, Esmaeli Javid G, Shirzad H, Karami N, Jahani M, Seyed Ahmadian M, Payvarmehr F, Mohraz M, et al. Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Arch Iran Med. 2010;13(4):318–23.
European Monitoring Centre for Drugs and Drug Addiction [EMCDDA]. European drug report: trends and developments. Luxembourg: Publications Office of the European Union; 2015.
University Mental Health Research Institute [UMHRI]. National Report to the EMCDDA: “Greece: New Developments, Trends”. Athens: Greek Reitox Focal Point of the EMCDDA; 2014.
Hellenic Center for Disease Control and Prevention [HCDCP]. HIV/AIDS Surveillance Report in Greece, 31-12-2014 (Issue 29). Athens: Hellenic Center for Disease Control and Prevention; 2014.
Kokkevi A, Alevizou S, Arvanitis Y, Liappas J, Stefanis C. AIDS-related behavior and attitudes among i.v. drug users in Greece. Int J Addict. 1992;27(1):37–50.
Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, Nikolopoulos GK, Malliori M, Salminen M, Suk JE, et al. Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill. 2011;16(48). Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20032.
Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, Antoniadou A, Lazanas M, Gargalianos P, Psychogiou M, Malliori M, Kremastinou J et al. HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. Euro Surveill. 2011;16(36). Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19962.
Hatzakis A, Sypsa V, Paraskevis D, Nikolopoulos G, Tsiara C, Micha K, Panopoulos A, Malliori M, Psichogiou M, Pharris A, et al. Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction. 2015;110(9):1453–67.
Sypsa V, Paraskevis D, Malliori M, Nikolopoulos GK, Panopoulos A, Kantzanou M, Katsoulidou A, Psichogiou M, Fotiou A, Pharris A, et al. Homelessness and other risk factors for HIV infection in the current outbreak among injection drug users in Athens, Greece. Am J Public Health. 2015;105(1):196–204.
Malliori M, Sypsa V, Psichogiou M, Touloumi G, Skoutelis A, Tassopoulos N, Hatzakis A, Stefanis C. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction. 1998;93(2):243–51.
Simon R, Donmall M, Hartnoll R, Kokkevi A, Ouwehand AW, Stauffacher M, Vicente J. The EMCDDA/Pompidou Group treatment demand indicator protocol: a European core item set for treatment monitoring and reporting. Eur Addict Res. 1999;5(4):197–207.
European Monitoring Centre for Drugs and Drug Addiction [EMCDDA]. DRID Guidance Module: behavioural indicators for people who inject drugs. Lisbon: EMCDDA; 2013.
Yen YF, Yen MY, Su LW, Li LH, Chuang P, Jiang XR, Deng CY. Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan. BMC Public Health. 2012;12:1066.
Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74–83.
Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6–7):777–813.
Des Jarlais DC, Marmor M, Paone D, Titus S, Shi Q, Perlis T, Jose B, Friedman SR. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996;348(9033):987–91.
Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997;349(9068):1797–800.
Gibson DR, Brand R, Anderson K, Kahn JG, Perales D, Guydish J. Two- to sixfold decreased odds of HIV risk behavior associated with use of syringe exchange. J Acquir Immune Defic Syndr. 2002;31(2):237–42.
Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M, Green S, Tunving K, Ljungberg B, Wodak A, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274(15):1226–31.
Strathdee SA, van Ameijden EJ, Mesquita F, Wodak A, Rana S, Vlahov D. Can HIV epidemics among injection drug users be prevented? AIDS. 1998;12(Suppl A):S71–9.
MacDonald M, Law M, Kaldor J, Hales JJ, Dore G. Effectiveness of needle and syringe programmes for preventing HIV transmission. Int J Drug Policy. 2003;14(5):353–7.
WHO. Effectiveness of Sterile Needle and Syringe Programming in Reducing HIV/AIDS Among Injecting Drug Users. Evidence for Action. Technical Paper. Geneva: WHO; 2004.
Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, Hope V, Van de Laar M. Human immunodeficiency virus among people who inject drugs: Is risk increasing in Europe? Euro Surveill. 2013;18(48):20648.
Terzidou M, Fotiou A. Explosion de VIH chez les consommateurs de drogues en Grèce pendant la crise économique [HIV outbreak among people who inject drugs in Greece during the economic crisis]. SWAPS. 2015;78:19–23.
Nikolopoulos GK, Sypsa V, Bonovas S, Paraskevis D, Malliori-Minerva M, Hatzakis A, Friedman SR. Big Events in Greece and HIV infection among people who inject drugs. Subst Use Misuse. 2015;50(7):1–14.
Nikolopoulos GK, Fotiou A. “Integrated interventions are dead. Long live sustainable integrated interventions!”—Austerity Challenges the Continuation of Effective Interventions in the Field of Drug Use-Related Harm Reduction. Subst Use Misuse. 2015;50(8–9):1220–2.
Friedman SR, Aral S. Social networks, risk-potential networks, health, and disease. J Urban Health. 2001;78(3):411–8.
Uchino BN. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. J Behav Med. 2006;29(4):377–87.
Fotopoulou M. Reasons behind Greek problem drug users’ decisions to quit using drugs and engage in treatment of their own volition: sense of self and the Greek filotimo. Addiction. 2014;109(4):627–34.
Lloyd JJ, Ricketts EP, Strathdee SA, Cornelius LJ, Bishai D, Huettner S, Havens JR, Latkin C. Social contextual factors associated with entry into opiate agonist treatment among injection drug users. Am J Drug Alcohol Abuse. 2005;31(4):555–70.
Burris S, Chiu J. Punitive Drug Law and the Risk Environment for Injecting Drug Users: Understanding the Connections. In: Working paper prepared for the Third Meeting of the Technical Advisory Group of the Global Commission on HIV and the Law, 7–9 July 2011. 2011.
Zurhold H, Stöver H. Inventory of harm reduction measures in European prisons. Frankfurt: Frankfurt University of Applied Sciences; 2013.
Degenhardt L, Mathers B, Guarinieri M, Panda S, Phillips B, Strathdee SA, Tyndall M, Wiessing L, Wodak A, Howard J. Meth/amphetamine use and associated HIV: implications for global policy and public health. Int J Drug Policy. 2010;21(5):347–58.
Johnson T, Fendrich M. Modeling sources of self-report bias in a survey of drug use epidemiology. Ann Epidemiol. 2005;15(5):381–9.